Treatment for Influenza Virus
Oseltamivir is the preferred antiviral medication for treating influenza A and B in both children and adults, and should be initiated as soon as possible—ideally within 48 hours of symptom onset—though treatment beyond this window remains beneficial for high-risk and severely ill patients. 1, 2, 3, 2
Who Should Receive Antiviral Treatment
Mandatory Treatment (Start Immediately, No Time Limit)
Antiviral therapy should be offered as early as possible to:
- Any hospitalized patient with suspected or confirmed influenza 1, 2
- Severe, complicated, or progressive illness regardless of setting 1, 2
- High-risk patients with any severity of illness, including:
Consider Treatment (Within 48 Hours Preferred)
- Otherwise healthy patients with mild-to-moderate influenza if treatment can start within 48 hours 1, 2
- Patients with high-risk household contacts (e.g., infants <6 months, immunocompromised family members) 1, 2
Antiviral Medications and Dosing
First-Line: Oseltamivir (Oral)
Adults: 75 mg twice daily for 5 days 2, 3, 2
Children ≥12 months (weight-based):
- ≤15 kg: 30 mg twice daily
15-23 kg: 45 mg twice daily
23-40 kg: 60 mg twice daily
Infants:
- 9-11 months: 3.5 mg/kg per dose twice daily
- 0-8 months (term): 3 mg/kg per dose twice daily
- Preterm infants: Dosing based on postmenstrual age (consult pediatric infectious disease) 2, 3, 2
Alternative Options
Zanamivir (Inhaled):
- Adults and children ≥7 years: 10 mg (two 5-mg inhalations) twice daily for 5 days
- Avoid in patients with chronic respiratory disease (asthma, COPD) due to bronchospasm risk 2, 3, 2
Peramivir (IV):
- Single 600 mg dose for adults; weight-based for children ≥6 months
- Option for patients unable to absorb oral medications 2, 3
Baloxavir marboxil (Oral):
- Single-dose treatment within 2 days of symptom onset
- Not recommended as monotherapy for severely immunocompromised patients, pregnant/breastfeeding women
- Should not be taken with dairy products, calcium-fortified beverages, or polyvalent cation supplements 1
Critical Clinical Considerations
Testing Strategy
- Do not delay treatment waiting for test results when influenza is circulating in the community 1, 2
- Initiate therapy based on clinical presentation, risk factors, and local epidemiology
- For hospitalized patients: Use molecular assays (RT-PCR) with high sensitivity/specificity 2, 3
- For severe lower respiratory disease: Test endotracheal aspirate or bronchoalveolar lavage fluid, as upper respiratory specimens may be falsely negative 4
Treatment Beyond 48 Hours
Still offer antiviral therapy for:
- Hospitalized patients
- Severe or progressive illness
- High-risk patients with ongoing symptoms
- Evidence suggests mortality benefit even when started >48 hours after onset 1, 2, 5, 4
Adjunctive Therapies to AVOID
Corticosteroids: Not recommended for influenza treatment (including critically ill patients) unless indicated for another reason (asthma/COPD exacerbation, septic shock). Observational data suggest increased mortality risk 4, 6, 7, 8
Antibiotics: Only use if bacterial co-infection is documented or strongly suspected 7, 8
Other agents not recommended: Macrolides, mTOR inhibitors, NSAIDs, convalescent plasma 7, 8
Supportive Care
- Optimize respiratory support using established ventilatory strategies
- Standard-dose oseltamivir is well absorbed in critically ill patients; higher doses show no additional benefit 4, 6, 9
- Monitor for complications: bacterial pneumonia, exacerbation of underlying conditions, respiratory failure
Chemoprophylaxis (Post-Exposure)
Oseltamivir is preferred for post-exposure prophylaxis within 48 hours of exposure 3, 2
Indications:
- High-risk unvaccinated/incompletely vaccinated individuals
- High-risk patients with recent vaccination (<2 weeks)
- Immunocompromised patients regardless of vaccination
- Household contacts of high-risk individuals
- Healthcare personnel during outbreaks 2
Dosing: Same as treatment dosing but once daily for 7-10 days 2, 3, 2
Common Pitfalls
- Don't wait for positive test results to start treatment in high-risk or hospitalized patients
- Don't withhold treatment beyond 48 hours in severe cases—benefit persists
- Don't use baloxavir in severely immunocompromised patients or with calcium-containing products
- Don't add corticosteroids routinely—associated with harm
- Don't assume vaccination eliminates need for treatment—vaccinated high-risk patients still benefit from antivirals 1, 2